The correlation between human papillomavirus positivity and abnormal cervical cytology resultdiffers by age among perimenopausal women

Journal of Lower Genital Tract Disease

Volumn 17, Issue 1, 2013, Pages 38-47

  Rositch, Anne F ^a   Silver, Michelle I ^a   Burke, Anne ^b   Viscidi, Raphael ^b   Chang, Kathryn ^a   Duke, Cindy M P ^b   Shen, Wen ^b   Gravitt, Patti E ^a,c  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c PERDANA UNIVERSITY   (Malaysia)

Author keywords

Cervical cancer; Cervical cytology; HPV; Human papillomavirus; Perimenopausal women; Screening

Indexed keywords

ADULT; ARTICLE; CLIMACTERIUM; CORRELATIONAL STUDY; FEMALE; HIGH RISK PATIENT; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; NONHUMAN; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PREVALENCE; PROSPECTIVE STUDY; QUESTIONNAIRE; UTERINE CERVIX CYTOLOGY; WART VIRUS;

ADULT; AGE FACTORS; COHORT STUDIES; FEMALE; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PERIMENOPAUSE; PREVALENCE; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; UTERINE CERVICAL NEOPLASMS;

EID: 84871313750     PISSN: 10892591     EISSN: 15260976     Source Type: Journal    
DOI: 10.1097/LGT.0b013e3182503402     Document Type: Article

References (23)

1. Kohler BA, Ward E, McCarthy BJ, Schymura MJ, Ries LA, Eheman C, et al. Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst 2011;103:714-36.
2. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 2007;197:346-55.
3. Clark JL, Lescano AG, Konda KA, Leon SR, Jones FR, Klausner JD, et al. Syndromic management and STI control in urban Peru. PLoS One 2009;4:e7201.
4. Moscicki AB, Shiboski S, Broering J, Powell K, Clayton L, Jay N, et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr 1998;132:277-84.
5. Smith JS, Melendy A, Rana RK, Pimenta JM. Age-specific prevalence of infection with human papillomavirus in females: a global review. J Adolesc Health 2008;43(suppl 4):S5-25.
6. Watson M, Saraiya M, Benard V, Coughlin SS, Flowers L, Cokkinides V, et al. Burden of cervical cancer in the United States, 1998-2003. Cancer 2008;113(suppl 10):2855-64.
7. Peto J, Gilham C, Deacon J, Taylor C, Evans C, Binns W, et al. Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br J Cancer 2004;91:942-53.
8. Rodriguez AC, Schiffman M, Herrero R, Hildesheim A, Bratti C, Sherman ME, et al. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst 2010;102:315-24.
9. Wright TC Jr, Stoler MH, Behrens CM, Apple R, Derion T, Wright TL. The ATHENA human papillomavirus study: design, methods, and baseline results. Am J Obstet Gynecol 2012;206:46e1-11.
10. Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras NE, Cheung L, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol 2011;12:663-72.
11. Marks MA, Viscidi RP, Chang K, Silver M, Burke A, Howard R, et al. Differences in the concentration and correlation of cervical immune markers among HPV positive and negative perimenopausal women. Cytokine 2011;56:798-803.
12. Gravitt PE, Peyton CL, Alessi TQ,Wheeler CM, Coutlee F, Hildesheim A, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000;38:357-61.
13. Coutlee F, Gravitt P, Kornegay J, Hankins C, Richardson H, Lapointe N, et al. Use of PGMY primers in L1 consensus PCR improves detection of human papillomavirus DNA in genital samples. J ClinMicrobiol 2002;40:902-7.
14. United States Preventative Services Task Force. Screening for Cervical Cancer U.S. Preventive Services Task Force Recommendation Statement Draft. Availabale at: http:// www.uspreventiveservicestaskforce.org/uspstf11/ cervcancer/ cervcancerrs.htm. Accessed March 26, 2012.
15. Castle PE, Fetterman B, Thomas Cox J, Shaber R, Poitras N, Lorey T, et al. The age-specific relationships of abnormal cytology and human papillomavirus DNA results to the risk of cervical precancer and cancer. Obstet Gynecol 2010;116:76-84.
16. Ronco G, Cuzick J, Segnan N, Brezzi S, Carozzi F, Folicaldi S, et al. HPV triage for low grade (L-SIL) cytology is appropriate for women over 35 in mass cervical cancer screening using liquid based cytology. Eur J Cancer 2007; 43:476-80.
17. Thrall MJ, Smith DA, Mody DR.Women 9or=30 years of age with low grade squamous intraepithelial lesion (LSIL) have low positivity rates when cotested for high-risk human papillomavirus: should we reconsider HPV triage for LSIL in older women? Diagn Cytopathol 2010;38:407-12.
18. Brismar-Wendel S, Froberg M, Hjerpe A, Andersson S, Johansson B. Age-specific prevalence of HPV genotypes in cervical cytology samples with equivocal or low-grade lesions. Br J Cancer 2009;101:511-7.
19. The ALTS Group. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. The Atypical Squamous Cells of Undetermined Significance/ Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS) Group. J Natl Cancer Inst 2000;92:397-402.
20. Castle PE, Jeronimo J, Schiffman M, Herrero R, Rodriguez AC, Bratti MC, et al. Age-related changes of the cervix influence human papillomavirus type distribution. Cancer Res 2006;66:1218-24.
21. Castle PE, Rodriguez AC, Porras C, Herrero R, Schiffman M, Gonzalez P, et al. A comparison of cervical and vaginal human papillomavirus. Sex Transm Dis 2007;34:849-55.
22. Castle PE, Schiffman M, Herrero R, Hildesheim A, Rodriguez AC, Bratti MC, et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis 2005;191:1808-16.
23. Maucort-Boulch D, Plummer M, Castle PE, Demuth F, Safaeian M, Wheeler CM, et al. Predictors of human papillomavirus persistence among women with equivocal or mildly abnormal cytology. Int J Cancer 2010;126:684-91.